Skip to main content
. 2020 Jan 30;106(2):483–494. doi: 10.3324/haematol.2019.230227

Figure 4.

Figure 4.

Blockade of iPAI-1 increases the sensitivity of chronic myeloid leukemia cells to tyrosine kinase inhibitor treatment. (A) Schema for experiments. (B) Quantitative real-time PCR analysis of the expression of BCR/ABL+ in bone marrow (BM) LSK cells of SCLtTAxBCR/ABL Tg mice that were treated with saline (n=10), imatinib (IM) alone (n=11), or IM plus plasminogen activator inhibitor-1 (PAI-1) inhibitor (TM5614) (n=12). (C) Kaplan Meier survival curves of SCLtTAxBCR/ABL Tg mice treated with saline (n=10), IM alone (n=10), or IM plus PAI-1 inhibitor (TM5614) (n=10). Data represent means ± standard deviation. Statistical significance was determined by Mann-Whitney unpaired t-test (B) or a log-rank non-parametric test (C). P<0.001, by a Kruskal-Wallis test. BCR: breakpoint cluster region; ABL: Abelson kinase: GFP: green fluorescent protein; LSK: Lineage (Lin)Sca1c-Kit.